Valuation: Incyte Corporation

Market Cap 23.35B 20.4B 18.73B 17.47B 33.12B 2,223B 33.68B 226B 87.41B 1,090B 87.66B 85.76B 3,756B P/E 2026 *
17x
P/E 2027 * 14.7x
Enterprise Value 18.33B 16.01B 14.71B 13.71B 26B 1,745B 26.44B 177B 68.62B 856B 68.82B 67.32B 2,949B EV / Sales 2026 *
3.25x
EV / Sales 2027 * 2.65x
Free-Float
98.11%
Yield 2026 *
-
Yield 2027 * -
1 day+2.68%
1 week+8.68%
Current month+3.09%
1 month+26.69%
3 months+21.82%
6 months+15.22%
Current year+18.32%
1 week 112.8
Extreme 112.8
118.69
1 month 96.09
Extreme 96.09
118.69
Current year 89.25
Extreme 89.25
118.69
1 year 66.85
Extreme 66.85
118.69
3 years 50.27
Extreme 50.27
118.69
5 years 50.27
Extreme 50.27
118.69
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 25/06/2025
Director of Finance/CFO 57 03/05/2026
President 62 04/06/2023
Director TitleAgeSince
Chairman 59 25/06/2025
Director/Board Member 72 19/01/2015
Director/Board Member 64 19/01/2015
Date Insider Type Main position Quantity % Market Cap.
06-07Free

Director

7,753 0.0039%
06-07
FBS Associates LLC
OtherCompany 0 0%
06-07
Baker Bros. Advisors LP
FreeCompany 15,506 0.0078%
Change 5-day change 1-year change 3-year change Capi.($)
+2.68%+8.68%+71.42%+87.73% 23.35B
+4.73%+5.50%+19.45%-8.94% 66.56B
-2.00%+0.31%+58.50%+226.08% 57.64B
+0.72%+40.60%+40.60%+40.60% 42.24B
+3.45%+6.04%-49.46%-55.91% 39.09B
+3.04%+7.01%+62.26%-24.13% 31.91B
+10.01%+33.49%+163.41%-34.35% 31.65B
+2.87%+16.83%+3.78%+192.67% 18.92B
-0.15%+2.75%+67.48%+130.07% 17.17B
+3.58%+10.76%+80.22%+348.78% 15.12B
Average +2.89%+8.38%+51.77%+90.26% 34.37B
Weighted average by Cap. +2.76%+7.49%+45.74%+67.83%

Financials

2026 *2027 *
Net sales 5.65B 4.93B 4.53B 4.22B 8.01B 537B 8.14B 54.54B 21.14B 264B 21.2B 20.74B 908B 6.22B 5.43B 4.99B 4.65B 8.82B 592B 8.97B 60.07B 23.28B 290B 23.34B 22.84B 1,000B
Net income 1.44B 1.26B 1.15B 1.08B 2.04B 137B 2.07B 13.88B 5.38B 67.11B 5.4B 5.28B 231B 1.67B 1.46B 1.34B 1.25B 2.37B 159B 2.41B 16.17B 6.27B 78.16B 6.28B 6.15B 269B
Net Debt -5.02B -4.39B -4.03B -3.76B -7.12B -478B -7.24B -48.49B -18.79B -234B -18.84B -18.44B -808B -6.87B -6.01B -5.52B -5.14B -9.75B -654B -9.92B -66.41B -25.74B -321B -25.81B -25.25B -1,106B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
02/07/26 US$116.86 +2.68% 2,632,596
01/07/26 US$113.81 +0.40% 1,711,033
30/06/26 US$113.36 -1.13% 1,830,643
29/06/26 US$114.66 +0.80% 1,532,380
26/06/26 US$113.75 +5.78% 3,795,266
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
116.86USD
Average target price
111.27USD
Spread / Average Target
-4.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock